Kristina Kramer, MD
Critical Care Medicine · Walnut Creek, CANPI 1598714511
Payments from drug & device makers
Across 345 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- GSK$2K
- AstraZeneca$2K
- United Therapeutics Corporation$380
- Genentech USA, Inc.$193
- Sunovion Pharmaceuticals Inc.$148
- plus $1K from 26 others
What the payments were for
- Food & beverage$7,124100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 88 | $2,030 |
| GSK | 95 | $1,690 |
| AstraZeneca | 69 | $1,552 |
| United Therapeutics Corporation | 15 | $380 |
| Genentech USA, Inc. | 12 | $193 |
| Sunovion Pharmaceuticals Inc. | 10 | $148 |
| Fisher & Paykel Healthcare Inc | 4 | $138 |
| Baxter Healthcare | 6 | $136 |
| 180 Medical, Inc. | 6 | $107 |
| Pulmonx Corporation | 5 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| Insmed, Inc. | 3 | $67 |
| AbbVie | 2 | $55 |
| Advanced Respiratory, Inc | 6 | $46 |
| Johnson & Johnson(2 entities) | 2 | $36 |
| Blue Earth Diagnostics | 2 | $36 |
| KARL Storz Endoscopy-america | 1 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| La Jolla Pharmaceutical Company | 1 | $31 |
| Bayer | 1 | $27 |
| Endo Pharmaceuticals Inc. | 2 | $25 |
| Pfizer | 1 | $25 |
| Mylan Specialty L.p. | 1 | $21 |
| Abiomed | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Grifols USA, LLC | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Resmed Corp | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Apria Healthcare LLC | 1 | $12 |
How this compares
$7,137 in reported general payments places this provider in the 85th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 63 | $1,042,562 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 607 | $562,118 |
| UptraviSelexipag | 12 | $280,457 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 201 | $173,629 |
| Breo ElliptaFluticasone/Vilanterol | 282 | $172,576 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 100 | $77,833 |
| Incruse ElliptaUmeclidinium Bromide | 85 | $52,933 |
| Spiriva RespimatTiotropium Bromide | 60 | $51,563 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $44,585 |
| EliquisApixaban | 28 | $31,882 |
| Arnuity ElliptaFluticasone Furoate | 50 | $25,387 |
| Pirfenidone | 16 | $24,782 |
| SymbicortBudesonide/Formoterol Fumarate | 84 | $23,378 |
| Spiriva HandihalerTiotropium Bromide | 14 | $21,071 |
| Qvar RedihalerBeclomethasone Dipropionate | 43 | $18,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $2,030 | $1,171,958223 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,690 | $857,5991,085 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $33 | $280,45712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,552 | $197,007285 claims |
| PfizerEliquis | $25 | $31,88228 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $15 | $18,60643 claims |
| Johnson & JohnsonXarelto | $36 | $6,10711 claims |
| MerckDulera | $13 | $5,57218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Walnut Creek
- Nader KamangarWalnut Creek$34K
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Cedric Franklin RutlandRiverside$3.2M
- Alex HakimLos Angeles$946K
- Praveen AkuthotaSan Diego$841K
- Wael El MaraachliSan Diego$751K
- Stephen RuossStanford$635K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.